IP Verse

Blueprint Medicines competitive analysis

Latest patents of Blueprint Medicines opposed by its competitors

Explore Blueprint Medicines's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 16, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3773589
Nov 1, 2023Ret Inhibitor For Use In Treating Cancer Having A Ret Alteration1
EP3856341
Sep 6, 2023Crystalline Forms Of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazinyl)-Pyrimidin-5-Yl)Ethan-1-Amine And Methods Of Making1

Latest publications and patents of Blueprint Medicines New

Explore the latest publications and patents granted to Blueprint Medicines, showcasing their recent innovations and technological advancements.

Last updated on: Oct 9, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Blueprint Medicines

EP3773589
Nov 1, 2023Ret Inhibitor For Use In Treating Cancer Having A Ret AlterationGranted And Under Opposition
EP3856341
Sep 6, 2023Crystalline Forms Of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazinyl)-Pyrimidin-5-Yl)Ethan-1-Amine And Methods Of MakingGranted And Under Opposition

Latest PTAB cases involving Blueprint Medicines

Discover the latest PTAB cases involving Blueprint Medicines, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Blueprint Medicines with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 16, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BLUEPRINT MEDICINES - 2 - -
SANDOZ1171619 -
TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBB20 - - -